WO2021109923A1 - Système de plate-forme de développement de médecine chinoise sûr, efficace et de haute qualité et procédé de réalisation - Google Patents

Système de plate-forme de développement de médecine chinoise sûr, efficace et de haute qualité et procédé de réalisation Download PDF

Info

Publication number
WO2021109923A1
WO2021109923A1 PCT/CN2020/132027 CN2020132027W WO2021109923A1 WO 2021109923 A1 WO2021109923 A1 WO 2021109923A1 CN 2020132027 W CN2020132027 W CN 2020132027W WO 2021109923 A1 WO2021109923 A1 WO 2021109923A1
Authority
WO
WIPO (PCT)
Prior art keywords
quality
effective
platform system
safe
chinese medicine
Prior art date
Application number
PCT/CN2020/132027
Other languages
English (en)
Chinese (zh)
Inventor
王梅
孙朋悦
Original Assignee
深圳市开物成务中医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市开物成务中医药科技有限公司 filed Critical 深圳市开物成务中医药科技有限公司
Publication of WO2021109923A1 publication Critical patent/WO2021109923A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing

Definitions

  • the invention relates to the technical field of plant medicine production and development, and more specifically, to a safe, effective, and high-quality Chinese medicine development platform system and an implementation method.
  • Botanicals are medicines used for medical purposes by part or all of plants. They are divided into traditional botanicals and modern botanicals. Plant extracts produced by modern science and technology are modern botanicals; botanicals can be divided into: whole (crude) Extracts-effective parts-effective components (active combination)-effective ingredients and other four levels, each level has the possibility of developing into medicines; the West is used to call botanicals natural medicines, the European Community
  • the defined botanical product is not just a single medicinal plant, it can be a combination of multiple herbal medicines (HERBAL MEDICAL PRODUCTS), containing specific plant active ingredients or plant extracts, and is used for medical purposes.
  • the technical problem to be solved by the present invention is to provide a safe, effective and high-quality Chinese medicine development platform system and an implementation method for the above-mentioned defects of the prior art.
  • a safe, effective, and high-quality Chinese medicine development platform system which includes a drug quality monitoring unit that monitors the quality of botanicals from the planting source, a multi-dimensional pharmacological unit that obtains or discovers drug activity data, and obtains clinical efficacy The clinical efficacy unit of the data.
  • the medicine quality monitoring unit includes a plant variety database.
  • the plant variety database is used to identify and identify each plant component for making botanicals.
  • the drug quality monitoring unit includes an extract and a mixture database
  • the extract and mixture database is used to extract various plant components for making botanicals Identification and identification of mixtures of substances and extracts.
  • the method for analyzing the quality of botanicals by the medicine quality monitoring unit includes fingerprint and/or statistics.
  • the multidimensional pharmacology unit includes a multivariate analysis unit, and the multivariate analysis unit is used to determine the effect of a multi-component botanical mixture on a set of living systems. The impact of the biological characteristics of the disease.
  • the method used when the multivariate analysis unit performs the determination is as follows:
  • step (c) Use multivariate analysis to determine the expected impact of the composition of the multi-component mixture sample shown in step (b) on the biological characteristics of the disease;
  • step (d) Use multivariate analysis in step (c) to determine the effective natural components or groups of natural components and their respective concentrations required to produce the expected effects on the biological characteristics of the disease.
  • the safe, effective and high-quality Chinese medicine development platform system of the present invention wherein the multi-analysis unit also includes a method when performing determination:
  • step (e) Prepare one or more natural product mixtures based on the information obtained in step (d), and predict the expected impact of these mixtures on the biological characteristics of the disease;
  • step (f) Determine the effect of the multi-component mixture prepared in step (e) on the biological characteristics of the disease.
  • the safe, effective and high-quality Chinese medicine development platform system of the present invention wherein the multi-dimensional pharmacology unit includes a biomarker tracking unit, and the biomarker tracking unit is used to continuously track the metabolite markers of the disease And feedback the status of the marker.
  • the clinical efficacy unit communicates with an external clinical trial institution to obtain clinical trial data for botanical drugs by the clinical trial institution.
  • a safe, effective and high-quality Chinese medicine development platform system implementation method is as follows:
  • the system biology technology platform of the present application can establish a quality control system starting from the source of the drug, and provide whole-process quality control for the safety and effectiveness of botanicals; it can prove the effectiveness of the complex components of botanicals, Drugs provide scientific basis; it can determine the metabolite markers of diseases, and provide scientific diagnostic methods for the dialectical treatment of botanicals; it can also detect the regulatory relationship between metabolites and different prescriptions, and provide a molecular level for the optimization of botanical formulas. in accordance with.
  • Figure 1 It is a schematic block diagram of a safe, effective and high-quality Chinese medicine development platform system for the implementation of the present invention
  • the safe, effective, and high-quality Chinese medicine development platform system of the implementation case of the present invention includes a drug quality monitoring unit 1 that monitors the quality of botanicals from the planting source, and obtains or discovers multi-dimensional pharmacology of drug activity data Unit 2, and clinical efficacy unit 3 for obtaining clinical efficacy data.
  • the system biology technology platform of this application can establish a quality control system that manages from the source of the drug, and provide process quality control for the safety and effectiveness of botanicals; it can prove the effectiveness of complex components of botanicals and provide scientific basis for botanicals; Determining the metabolite markers of the disease provides scientific diagnostic methods for the dialectical treatment of botanicals; it can also detect the regulatory relationship between metabolites and different prescriptions, and provide a basis for the optimization of botanical formulas at the molecular level.
  • the drug quality monitoring unit includes a plant variety database.
  • the plant variety database is used to identify and identify the plant components used to make botanicals;
  • the plant variety database data of the platform can be compared to verify the authenticity and quality level of plant components to ensure the quality of plant components. reliable.
  • the drug quality monitoring unit includes an extract and a mixture database, and the extract and mixture database is used to identify and identify the extracts of various plant components and the mixtures of the extracts used to make the botanical medicine.
  • the data of color, transparency, and sedimentation state can be collected and uploaded offline, and the data can be compared by the extract and mixture database of the platform. Ensure the reliable quality of the extracts of plant components and the mixture of extracts.
  • the method for analyzing the quality of the botanical by the drug quality monitoring unit includes fingerprint and/or statistics.
  • the multidimensional pharmacology unit includes a multivariate analysis unit.
  • the multivariate analysis unit is used to determine the effect of a multi-component botanical mixture on the biological characteristics of a group of diseases in a living system.
  • the method used in the multivariate analysis unit for determination is as follows:
  • step (c) Use multivariate analysis to determine the expected impact of the composition of the multi-component mixture sample shown in step (b) on the biological characteristics of the disease;
  • step (d) Use multivariate analysis in step (c) to determine the effective natural components or groups of natural components and their respective concentrations required to produce the expected impact on the biological characteristics of the disease.
  • the multivariate analysis unit also includes a method when performing the determination:
  • step (e) Prepare one or more natural product mixtures based on the information obtained in step (d), and predict the expected impact of these mixtures on the biological characteristics of the disease;
  • step (f) Determine the effect of the multi-component mixture prepared in step (e) on the biological characteristics of the disease.
  • a multi-component botanical medicine mixture can be developed within a prescribed quality range. Due to different culture conditions, the quality of each natural component or group of natural components may be locally different. If one or more natural components or one or more groups of natural components do not have the required quality, the multi-component mixture can be adjusted for one or more natural components or groups of natural components in order to achieve the desired pairing. The effect of the biological characteristics of the disease.
  • it can be determined by adjusting the amount of one or more natural components or one or more groups of natural components, so as to obtain the required amount of one or more natural components or one or more groups of natural components. Concentration to ensure that the multi-component mixture will have the expected impact on the biological characteristics of the disease.
  • a multi-component botanical mixture is a botanical component or a mixture of botanical components, which is produced not through chemical synthesis but through natural processes.
  • a multi-component herbal mixture will contain two or more herbs, and these herbs may contain many different ingredients.
  • MDP Multidimensional Pharmacology
  • the above method is not limited to only measuring the biological effects and synergistic effects in the mammalian system, and can also solve all possible biological system forms, including complex compounds from the same life combination.
  • the body fluid characteristics of plasma samples from the control group (reference group) and patient group (biometric disease symptom group) can be used to measure as many components as possible and to evaluate a single group between the two groups.
  • biomarkers/surrogate markers detect new biomarkers/surrogate markers, predict toxicological or pharmacological reactions, or develop new intervention pathways.
  • the biological characteristics to be determined in step (a) preferably include one or more of metabolism, gene expression and/or protein characteristics, and a combination of these characteristics can also be used.
  • step (a) priority is given to determining the biological characteristics of at least one body fluid or at least one tissue.
  • step (a) one or more of the following biomarkers are used to determine biological characteristics: genes, transcripts, proteins, metabolites, and (trace) elements.
  • step (b) at least one spectrometric technique, at least one based on electronic transition technique or at least one chromatographic technique is preferably used to determine the influence of a series of samples of the multi-component mixture on the biological characteristics of the disease.
  • step (c) at least one spectrometric technique, at least one based on electronic transition technique or at least one chromatographic technique is preferably used to determine the composition of the sample.
  • step (d) at least one spectrometric technique, at least one technique based on electronic transition or at least one chromatographic technique is preferably used to identify the effective components or component groups and their respective concentration.
  • step (f) at least one spectrometric technique, at least one technique based on electronic transition or at least one chromatographic technique is preferably used to identify the effective components or component groups required to affect the organism and their respective concentration.
  • the multi-component mixture used in the present invention can be any multi-component mixture that has a (potential) effect on the biological characteristics of the disease.
  • This multi-component mixture can be any botanical.
  • At least one spectrometry technique is preferably used.
  • the nuclear magnetic resonance technique (“NMR”) or mass spectrometry technique (“MS”) can be suitably used, with the latter technique focusing on a limited number of small molecule compounds.
  • Small molecule compounds include but are not limited to lipids, steroids, amino acids, organic acids, bile acids, eicosanoids, peptides, carbohydrates and trace elements.
  • At least nuclear magnetic resonance technology and/or mass spectrometry technology are preferably used, and mass spectrometry technology is preferred in the field of protein analysis (proteomics).
  • NMR sample preparation can usually be very simple to use freeze-drying and reconstruction in D2O, because the focus is on high-concentration components, that is, typical concentrations >100 ng/ml.
  • sample preparation methods can be used, for example, using polarity-based methods or derivatization methods for GC-MS and LC-MS.
  • spectral data obtained from one or more platforms can be used, including but not limited to mass spectrometry, nuclear magnetic resonance, liquid chromatography ( "LC"), gas chromatography (“GC”), high performance liquid chromatography (“HPLC”), capillary electrophoresis (“CE”), and any known form of coupling in low-resolution or high-resolution mode
  • mass spectrometry such as LC-MS, GC-MS, CE-MS, LC-UV, MS-MS, MSn, etc.
  • component-specific detectors such as laser-induced fluorescence and electrochemical detection, various typical data can also be obtained.
  • spectral data includes data from any spectrometric or chromatographic technique.
  • Spectrometry techniques include but are not limited to nuclear magnetic resonance spectroscopy, infrared spectroscopy, Raman spectroscopy and ultraviolet spectroscopy, and others also include mass spectroscopy.
  • Chromatography techniques include but are not limited to liquid chromatography, gas chromatography and electrophoresis.
  • the multi-dimensional pharmacology unit includes a biomarker tracking unit, and the biomarker tracking unit is used to continuously track the metabolite marker of the disease and feed back the status of the marker;
  • biomarkers are defined as features that are objectively measured and evaluated: normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions.
  • Biomarkers can be genes, transcripts, proteins, metabolites (trace elements) or any combination of these components.
  • the clinical efficacy unit maintains contact with an external clinical trial institution to obtain clinical trial data for botanicals by the clinical trial institution.
  • a plant-to-patient system biology method according to the above-mentioned safe, effective and high-quality Chinese medicine development platform system, its realization method is as follows:
  • the system biology technology platform of this application can establish a quality control system starting from the source of the drug, and provide full quality management for the safety and effectiveness of botanicals; it can prove the effectiveness of the complex components of botanicals, and provide scientific basis for botanicals; it can determine the disease
  • the metabolite markers provide scientific diagnostic methods for the dialectical treatment of botanicals; it can also detect the regulatory relationship between metabolites and different prescriptions, and provide a basis for the optimization of botanical formulas at the molecular level.

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Computing Systems (AREA)
  • Biophysics (AREA)
  • Software Systems (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Data Mining & Analysis (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention porte sur un système de plate-forme de développement de médecine chinoise sûr, efficace et de haute qualité et sur son procédé de réalisation. Le système de plate-forme comprend : une unité de surveillance de qualité de la médecine (1) pour surveiller la qualité de la médecine par les plantes à partir d'une source de plantation, une unité de pharmacologie multidimensionnelle (2) pour acquérir ou découvrir des données d'effet d'activité de médecine, et une unité d'effet curatif clinique (3) pour acquérir des données d'effet curatif clinique. Le système de plate-forme peut établir un système de contrôle de qualité commençant à partir d'une source de médicament, ce qui permet de fournir une gestion de la qualité de tout le processus pour la sécurité et l'efficacité de la médecine par les plantes ; peut prouver l'efficacité de composants complexes de la médecine par les plantes, ce qui permet de fournir une base scientifique pour l'application clinique de la médecine par les plantes ; peut déterminer des marqueurs de métabolites de maladies, ce qui permet de fournir des moyens de diagnostic scientifiques pour le traitement dialectique de la médecine par les plantes ; et peut également déterminer une relation de régulation et de contrôle entre des métabolites et des prescriptions différentes, ce qui permet d'obtenir une base pour l'optimisation de formules de médecine par les plantes à un niveau moléculaire.
PCT/CN2020/132027 2019-12-03 2020-11-27 Système de plate-forme de développement de médecine chinoise sûr, efficace et de haute qualité et procédé de réalisation WO2021109923A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911220732.0A CN111180007A (zh) 2019-12-03 2019-12-03 一种安全、有效、高质量中药开发平台系统及实现方法
CN201911220732.0 2019-12-03

Publications (1)

Publication Number Publication Date
WO2021109923A1 true WO2021109923A1 (fr) 2021-06-10

Family

ID=70656216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/132027 WO2021109923A1 (fr) 2019-12-03 2020-11-27 Système de plate-forme de développement de médecine chinoise sûr, efficace et de haute qualité et procédé de réalisation

Country Status (2)

Country Link
CN (1) CN111180007A (fr)
WO (1) WO2021109923A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111180007A (zh) * 2019-12-03 2020-05-19 深圳市开物成务中医药科技有限公司 一种安全、有效、高质量中药开发平台系统及实现方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081750A1 (en) * 2000-12-22 2002-06-27 Michael Ernest Drug evaluation operating principles
CN1875274A (zh) * 2003-09-05 2006-12-06 荷兰应用科学研究会(Tno) 用于确定多组分天然产品混和物对一组活体系统体内的疾病的生物特征谱的影响以及基于天然产品的药物的开发和质量控制的方法
CN101299022A (zh) * 2008-06-20 2008-11-05 河南中医学院 利用近红外光谱技术评价中药药材综合质量的方法
CN108593863A (zh) * 2018-05-08 2018-09-28 南通市第二人民医院 一种中药提取过程中的在线检测方法与装置
CN111180007A (zh) * 2019-12-03 2020-05-19 深圳市开物成务中医药科技有限公司 一种安全、有效、高质量中药开发平台系统及实现方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101051041A (zh) * 2006-04-06 2007-10-10 辛宁 一种中药定量指纹图谱的建立方法
CN102100706A (zh) * 2009-12-18 2011-06-22 中国科学院大连化学物理研究所 一种应用代谢组学对中成药质量评价的方法
CN108152390A (zh) * 2017-12-04 2018-06-12 武夷学院 一种金线莲hplc指纹图谱分析方法
CN109270187B (zh) * 2018-11-02 2022-05-10 江苏省中医院 一种基于代谢组学与全成分半定量分析的中药制剂质量评价方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081750A1 (en) * 2000-12-22 2002-06-27 Michael Ernest Drug evaluation operating principles
CN1875274A (zh) * 2003-09-05 2006-12-06 荷兰应用科学研究会(Tno) 用于确定多组分天然产品混和物对一组活体系统体内的疾病的生物特征谱的影响以及基于天然产品的药物的开发和质量控制的方法
CN101299022A (zh) * 2008-06-20 2008-11-05 河南中医学院 利用近红外光谱技术评价中药药材综合质量的方法
CN108593863A (zh) * 2018-05-08 2018-09-28 南通市第二人民医院 一种中药提取过程中的在线检测方法与装置
CN111180007A (zh) * 2019-12-03 2020-05-19 深圳市开物成务中医药科技有限公司 一种安全、有效、高质量中药开发平台系统及实现方法

Also Published As

Publication number Publication date
CN111180007A (zh) 2020-05-19

Similar Documents

Publication Publication Date Title
Ganti et al. Urine metabolomics for kidney cancer detection and biomarker discovery
Wang et al. Pattern recognition approaches and computational systems tools for ultra performance liquid chromatography–mass spectrometry-based comprehensive metabolomic profiling and pathways analysis of biological data sets
Griffin The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball?
Zhang et al. Metabolomics study of type 2 diabetes using ultra-performance LC-ESI/quadrupole-TOF high-definition MS coupled with pattern recognition methods
CN107247095A (zh) 一种基于代谢组学分析的用于抗氧化衰老药物筛选的大鼠模型的构建方法
Lan et al. Towards polypharmacokinetics: pharmacokinetics of multicomponent drugs and herbal medicines using a metabolomics approach
CN108588210B (zh) 包含生物小分子及基因的肝损伤生物标志物、方法及应用
Chau et al. Recipe for uncovering the bioactive components in herbal medicine
CN109507337A (zh) 一种基于血尿中代谢产物预测甘地胶囊治疗糖尿病肾病机制的新方法
JP4675896B2 (ja) 生体系のグループ内の疾病の生物学的プロファイルに対する多成分天然産物混合物の影響を決定するための方法、並びに天然産物に基づく医薬品の開発及び品質管理
Mattoli et al. Mass spectrometry‐based metabolomic analysis as a tool for quality control of natural complex products
Singh et al. Personalised therapeutic management of epileptic patients guided by pathway-driven breath metabolomics
MacDonald et al. Laser capture microdissection–targeted mass spectrometry: a method for multiplexed protein quantification within individual layers of the cerebral cortex
WO2021109923A1 (fr) Système de plate-forme de développement de médecine chinoise sûr, efficace et de haute qualité et procédé de réalisation
Liu et al. Discovery of potential Q‐marker of traditional Chinese medicine based on chemical profiling, chemometrics, network pharmacology, and molecular docking: Centipeda minima as an example
Wang et al. Chinmedomics: the integration of serum pharmacochemistry and metabolomics to elucidate the scientific value of traditional Chinese medicine
Wang et al. Origin of chinmedomics
Mitra et al. Identification of analytical factors affecting complex proteomics profiles acquired in a factorial design study with analysis of variance: simultaneous component analysis
Welz et al. Rapid targeted method of detecting abused piperazine designer drugs
Eshawu et al. Metabolomics of natural samples: A tutorial review on the latest technologies
Liu et al. Monitoring the quality consistency of Weibizhi tablets by micellar electrokinetic chromatography fingerprints combined with multivariate statistical analyses, the simple quantified ratio fingerprint method, and the fingerprint–efficacy relationship
Yip et al. Gas chromatography/mass spectrometry-based metabonomics
Zhu et al. Identification and quantification of nine compounds in Fangwen Jiuwei decoction by liquid chromatography–mass spectrometry
Lindon et al. The development of metabolic phenotyping—a historical perspective
Lee et al. Experimental design in metabolomics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20895438

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20895438

Country of ref document: EP

Kind code of ref document: A1